These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 23032250)

  • 1. Psoriasis affects patient's quality of life more seriously in female than in male in Japan.
    Mabuchi T; Yamaoka H; Kojima T; Ikoma N; Akasaka E; Ozawa A
    Tokai J Exp Clin Med; 2012 Sep; 37(3):84-8. PubMed ID: 23032250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study.
    Tang MM; Chang CC; Chan LC; Heng A
    Int J Dermatol; 2013 Mar; 52(3):314-22. PubMed ID: 23414155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring quality of life in patients with psoriasis using the Arabic version for Morocco of the Dermatology Life Quality Index.
    Khoudri I; Lamchahab FZ; Ismaili N; Senouci K; Hassam B; Abouqal R
    Int J Dermatol; 2013 Jul; 52(7):795-802. PubMed ID: 23488573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R; Willian MK; Okun MM; Thompson CS; Revicki DA
    Health Qual Life Outcomes; 2006 Sep; 4():71. PubMed ID: 17005043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab.
    Torii H; Sato N; Yoshinari T; Nakagawa H;
    J Dermatol; 2012 Mar; 39(3):253-9. PubMed ID: 22211581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
    Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T
    J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriasis has a major secondary impact on the lives of family members and partners.
    Eghlileb AM; Davies EE; Finlay AY
    Br J Dermatol; 2007 Jun; 156(6):1245-50. PubMed ID: 17459044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis.
    Fernandez-Peñas P; Jones-Caballero M; Espallardo O; García-Díez A
    Br J Dermatol; 2012 Apr; 166(4):884-7. PubMed ID: 22229951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Willingness-to-pay and quality of life in patients with vitiligo.
    Radtke MA; Schäfer I; Gajur A; Langenbruch A; Augustin M
    Br J Dermatol; 2009 Jul; 161(1):134-9. PubMed ID: 19298268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of active and stable psoriasis on health-related quality of life: the PSO-LIFE study.
    Daudén E; Herrera E; Puig L; Sánchez-Carazo JL; Toribio J; Perulero N
    Actas Dermosifiliogr; 2013 Oct; 104(8):685-93. PubMed ID: 23958428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychometric properties of the Chinese version of Dermatology Life Quality Index (DLQI) in 851 Chinese patients with psoriasis.
    He Z; Lu C; Basra MK; Ou A; Yan Y; Li L
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):109-15. PubMed ID: 22145712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Narrowband ultraviolet B phototherapy improves the quality of life in patients with psoriasis.
    Al Robaee AA; Alzolibani AA
    Saudi Med J; 2011 Jun; 32(6):603-6. PubMed ID: 21666943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis.
    Bergstrom KG; Arambula K; Kimball AB
    Cutis; 2003 Nov; 72(5):407-11. PubMed ID: 14655784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between quality of life and the severity of psoriasis in Turkey.
    Çakmur H; Derviş E
    Eur J Dermatol; 2015 Apr; 25(2):169-76. PubMed ID: 25655046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life.
    Katugampola RP; Hongbo Y; Finlay AY
    Br J Dermatol; 2005 Jun; 152(6):1256-62. PubMed ID: 15948990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study.
    Daudén E; Pujol RM; Sánchez-Carazo JL; Toribio J; Vanaclocha F; Puig L; Yébenes M; Sabater E; Casado MA; Caloto MT; Aragón B;
    Actas Dermosifiliogr; 2013 Nov; 104(9):807-14. PubMed ID: 23827342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI).
    Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):452-6. PubMed ID: 24911993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.